# Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Canonical URL: https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-9ba83e8c
Ticker: HEPA
Company: Hepion Pharmaceuticals
Source: Hepion Pharmaceuticals
Published: 2025-06-25 12:30 EST
## Summary

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is...

## Article Body
Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.

About Hepion Pharmaceuticals

Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.

For further information, please contact:

Hepion Pharmaceuticals info@hepionpharma.com
## Recent Company News
- 2026-03-03 12:35 EST — [Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-in-licenses-ctrna-biomarker-assay-to-facilitate-early-dia-5419c60d) — Source: Hepion Pharmaceuticals
- 2025-06-25 12:30 EST — [Hepion Pharmaceuticals Successfully Completes Application to the OTCQB](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-9ba83e8c) — Source: Hepion Pharmaceuticals
- 2025-06-16 12:30 EST — [Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-dr-kaouthar-lbiati-as-interim-chief-executive-o-a94f00a0) — Source: Hepion Pharmaceuticals
- 2025-05-12 20:30 EST — [Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-b29aaf82) — Source: Hepion Pharmaceuticals
- 2025-05-07 12:30 EST — [Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-executes-binding-letter-of-intent-with-new-day-diagnostic-4fed3351) — Source: Hepion Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)